| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mL |
|
||
| 250mL |
|
||
| 500mL |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
solvent, plasticizer, surfactant, ointment and suppository base, and tablet and capsule lubricant
|
|---|---|
| ln Vitro |
The water soluble polymers studied were; polyethylene glycol (PEG) (molecular weight, Mw, 300 and 1000) (neutral), polyamine (FL15) (Mw 5000) (cationic) and polyacrylic acid, PAA, (Mw 2000) (charge dependant on pH) to establish the effect of polymer charge on the nature and extent of adsorption. XRD and ATR-FTIR spectroscopy have shown that water soluble polymers adsorb onto clay dispersions and are stable when deposited as thin solid films. XRD indicates that PEG stacks as either one or two layers whereas PAA and FL15 are restricted to a single layer between the clay lamellae. ATR-FTIR spectroscopy showed that FL15 penetrated the Na–SWy-1 films which contained low loadings of PEG without displacing any of the resident PEG. When a bilayer of PEG was present, FL15 did not penetrate into the film. Both PAA and PEG adsorbed onto FL15 loaded Na–SWy-1 films irrespective of FL15 loading or the molecular weight of the PEG. ATR-FTIR indicated that significant adsorption occurred in under 30 s and the adsorption rate was not influenced by the presence of a second polymer preloaded into the clay. [1]
The FDA has approved polyethylene glycol (PEG) as a carrier or matrix in food, cosmetics, and drugs, including injectable, topical, rectal, and nasal preparations. PEG is almost non-toxic and can be completely eliminated from the body through the kidneys (for PEG<30 kDa) or feces (for PEG>20 kDa). PEG lacks immunogenicity, and antibodies against PEG are only produced in rabbits when PEG binds to high immunogenic proteins. [2,3] |
| ln Vivo |
Up to 50% of PEG300 can be used in intravenous and intramuscular injection forms, with no toxic effects. When taken orally, the maximum percentage of PEG300 can reach 90%.[4,5]
|
| References |
[1]. J.Billingham, et al. Adsorption of polyamine, polyacrylic acid and polyethylene glycol on montmorillonite: An in situ study using ATR-FTIR. Volume 14, Issue 1, March 1997, Pages 19-34.
[2]. Lee CC, et al. Structural basis of polyethylene glycol recognition by antibody. J Biomed Sci. 2020 Jan 7;27(1):12. [3]. Harris JM, et al. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003 Mar;2(3):214-21. [4]. Xiaoqin Wang, et al. Injectable silk-polyethylene glycol hydrogels. Acta Biomater. 2015 Jan;12:51-61. [5]. Ellen Weisberg, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20. |
| Molecular Formula |
(CH2CH2O)N
|
|---|---|
| Molecular Weight |
300
|
| CAS # |
25322-68-3
|
| Related CAS # |
PEG300;25322-68-3;PEG400;25322-68-3;PEG2000;25322-68-3
|
| Appearance |
Colorless to light yellow liquid
|
| SMILES |
OCCCCOC[H].[n]
|
| Synonyms |
Polyethylene glycol 300; PEG-300; PEG300
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~333 mM)
H2O : ≥ 50 mg/mL (~166 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3333 mL | 16.6667 mL | 33.3333 mL | |
| 5 mM | 0.6667 mL | 3.3333 mL | 6.6667 mL | |
| 10 mM | 0.3333 mL | 1.6667 mL | 3.3333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA